Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 12/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244193 | 0.91 | ALDH1A1 (0.49) | ALDH1A1DDR1SMN1; SMN2CDK1HPGD | |
| SCHEMBL14035784 | 0.84 | L3MBTL1 (0.47) | ALDH1A1DDR1L3MBTL1 | |
| SCHEMBL2855266 | 0.80 | DDR1 (0.39) | ALDH1A1DDR1SMN1; SMN2HPGD | |
| SCHEMBL5038734 | 0.79 | ALDH1A1 (0.40) | ALDH1A1DDR1MAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL14035945 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MAPK1SMN1; SMN2L3MBTL1CDK1 | |
| Trifluoroacetic Acid SCHEMBL4613399 | 0.78 | DDR1 (0.40) | DDR1 | |
| SCHEMBL2535835 | 0.77 | ALDH1A1 (0.50) | ALDH1A1MAPK1SMN1; SMN2CDK1HPGD | |
| SCHEMBL2873949 | 0.73 | MAPK1 (0.42) | ALDH1A1MAPK1SMN1; SMN2L3MBTL1CDK1 | |
| SCHEMBL5038736 | 0.71 | L3MBTL1 (0.43) | ALDH1A1MAPK1SMN1; SMN2L3MBTL1CDK1 | |
| SCHEMBL2542795 | 0.70 | ALDH1A1 (0.56) | ALDH1A1CDK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910298-B1 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | ALDH1A1 2963/4885DDR1 2051/4885MAPK1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.